Stay updated on Grapiprant and Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T13:56:50.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The page has been updated to include new information about the study's identifier and collaborators, while significant details about the study's design and inclusion/exclusion criteria have been removed.
    Difference
    23%
    Check dated 2025-04-16T02:03:41.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.1%
    Check dated 2025-04-08T22:38:55.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.1%
    Check dated 2025-04-01T18:23:56.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    2%
    Check dated 2025-03-03T22:23:02.000Z thumbnail image
  8. Check
    87 days ago
    Change Detected
    Summary
    The web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    2%
    Check dated 2025-02-10T09:51:48.000Z thumbnail image

Stay in the know with updates to Grapiprant and Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.